Cargando…

High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL

It remains challenging in chronic lymphocytic leukemia (CLL) to distinguish between patients with favorable and unfavorable time-to-first treatment (TTFT). Additionally, the downstream protein correlates of well-known molecular features of CLL are not always clear. To address this, we selected 40 CL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hengeveld, Paul J., Kolijn, P. Martijn, Demmers, Jeroen A.A., Doff, Wouter, Dubois, Julie M.N., Rijken, Melissa, Assmann, Jorn L.J.C., van der Straten, Lina, Boiten, Henk Jan, Gussinklo, Kirsten J., Valk, Peter J.M., Faber, Laura M., Westerweel, Peter E., Kater, Arnon P., Levin, Mark-David, Langerak, Anton W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508458/ https://www.ncbi.nlm.nih.gov/pubmed/37731707 http://dx.doi.org/10.1097/HS9.0000000000000951

Ejemplares similares

P634: EARLY-STAGE MEASURABLE RESIDUAL DISEASE DYNAMICS AND IGHV REPERTOIRE RECONSTITUTION DURING VENETOCLAX AND OBINUTUZUMAB TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Hengeveld, Paul, et al.
Publicado: (2023)

Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features
por: van der Straten, Lina, et al.
Publicado: (2021)

The THEMIS Mission
por: Burch, J. L, et al.
Publicado: (2009)

Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia
por: Hengeveld, P. J., et al.
Publicado: (2023)

Themis : nueva generación /
Publicado: (2010)

Context-dependent T-cell Receptor Gene Repertoire Profiles in Proliferations of T Large Granular Lymphocytes
por: Assmann, Jorn L.J.C., et al.
Publicado: (2023)

The "CAT" project ("Cherenkov Array at Themis")
por: Degrange, B, et al.
Publicado: (1994)

Porta themis fiscal 2004 /
por: Calvo Nicolau, Enrique
Publicado: (2004)

Micro Themis constitución política
por: Calvo Nicolau, Enrique
Publicado: (1989)

Miicro Themis Fiscal 1991
por: Calvo Nicolau, Enrique
Publicado: (1991)

Cherenkov array at Thémis: CAT project report
por: Degrange, B, et al.
Publicado: (1993)

Characteristics of the Flank Magnetopause: THEMIS Observations
por: Haaland, S., et al.
Publicado: (2019)

P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL
por: Kater, Arnon, et al.
Publicado: (2023)

Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells
por: van Bruggen, J. A. C., et al.
Publicado: (2022)

TRB sequences targeting ORF1a/b are associated with disease severity in hospitalized COVID‐19 patients
por: Assmann, Jorn L.J.C., et al.
Publicado: (2021)

Themis-associated phosphatase activity controls signaling in T cell development
por: Mehta, Monika, et al.
Publicado: (2018)

Themis2 Is Not Required for B Cell Development, Activation, and Antibody Responses
por: Hartweger, Harald, et al.
Publicado: (2014)

Prognosis of IGLV3-21(R110) chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysis
por: Hengeveld, Paul J., et al.
Publicado: (2023)

Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL
por: Collins, McKensie A., et al.
Publicado: (2022)

P601: GENETIC DRIVERS IN THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA DEVELOPMENT AS EARLY AS 16 YEARS BEFORE DIAGNOSIS
por: Martijn Kolijn, Pieter, et al.
Publicado: (2023)

Genetic drivers in the natural history of chronic lymphocytic leukemia development as early as 16 years before diagnosis
por: Kolijn, P. Martijn, et al.
Publicado: (2023)

Themis sets the signal threshold for positive and negative selection in T-cell development
por: Fu, Guo, et al.
Publicado: (2013)

Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL
por: Griffin, Rosalie, et al.
Publicado: (2023)

Differential Function of Themis CABIT Domains during T Cell Development
por: Okada, Toshiyuki, et al.
Publicado: (2014)

A THEMIS:SHP1 complex promotes T-cell survival
por: Paster, Wolfgang, et al.
Publicado: (2015)

Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study
por: Ramassone, Alice, et al.
Publicado: (2019)

Disseminated cryptococcal disease during treatment with idelalisib and corticosteroids for follicular lymphoma
por: Hengeveld, Paul J, et al.
Publicado: (2020)

Themis controls thymocyte selection through regulation of T cell receptor-mediated signaling
por: Fu, Guo, et al.
Publicado: (2009)

A Major Subset of Mutated CLL Expresses Affinity-selected and Functionally Proficient Rheumatoid Factors
por: Janssen, Jerry, et al.
Publicado: (2021)

Themis2 regulates natural killer cell memory function and formation
por: Nabekura, Tsukasa, et al.
Publicado: (2023)

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
por: Stilgenbauer, Stephan, et al.
Publicado: (2018)

Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL
por: Haselager, Marco, et al.
Publicado: (2021)

Themis controls T cell activation, effector functions, and metabolism of peripheral CD8(+) T cells
por: Gautam, Namrata, et al.
Publicado: (2023)

In Vitro 3D Spheroid Culture System Displays Sustained T Cell-dependent CLL Proliferation and Survival
por: Haselager, Marco V., et al.
Publicado: (2023)

In vivo functional mapping of the conserved protein domains within murine Themis1
por: Zvezdova, Ekaterina, et al.
Publicado: (2014)

How should the ticagrelor be used? The point after the TWILIGHT and THEMIS-PCI studies
por: Gatto, Laura, et al.
Publicado: (2020)

Photoionization Loss of Mercury's Sodium Exosphere: Seasonal Observations by MESSENGER and the THEMIS Telescope
por: Jasinski, Jamie M., et al.
Publicado: (2021)

Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)
por: Al-Kali, Aref, et al.
Publicado: (2010)

Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation
por: Kielbassa, Karoline, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dsjsn9mglcocfedr2si0scg1ts